anti-αvβ3 G4

anti-αvβ3 G4 is a fully human IgG4 monoclonal antibody designed to target integrin αvβ3, a marker of tumor stemness and drug resistance in epithelial cancers. Developed by Alpha Beta Therapeutics and researchers at UC San Diego, it is a re-engineered variant of the IgG1 antibody etaracizumab. Unlike its predecessor, which relied on NK cell-mediated cytotoxicity, anti-αvβ3 G4 is optimized to engage tumor-associated macrophages (TAMs) by activating the CD64 (FcγRI) receptor. This engagement triggers TAM-mediated cytotoxicity through the upregulation of inducible nitric oxide synthase (iNOS), demonstrating superior antitumor activity in lung cancer models where NK cell infiltration is limited.

Other names

IgG4 variant of etaracizumabIgG-4 variant of etaracizumabIgG 4 variant of etaracizumab